Bruce Samuels
Internal Medicine · Covington, LANPI 1164422119
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $180,780 of the $200,457 with a category attached, or 90.2%. Abbott accounts for 99.7% of it on its own, with 9 other manufacturers making up the rest. Among internal medicine clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 171 payments — averaging $1172.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$200K
- Philips North America LLC$239
- Indivior Inc.$150
- Orexo US, Inc.$97
- Boehringer Ingelheim$83
- Pfizer$29
- plus $64 from 4 others
What the payments were for
- Consulting fees$180,78090%
- Travel & lodging$17,6209%
- Food & beverage$2,0561%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 140 | $199,794 |
| Philips North America LLC | 6 | $239 |
| Indivior Inc. | 8 | $150 |
| Orexo US, Inc. | 5 | $97 |
| Boehringer Ingelheim | 7 | $83 |
| Pfizer | 1 | $29 |
| Lilly USA, LLC | 1 | $19 |
| Amarin Pharma, Inc. | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| GSK | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OPTIS$48,050
- Xience V coronary stent system$39,000
- COROFLOW$37,915
- Dragonfly OCT$35,250
- PRESSUREWIRE$24,045
- DRAGONFLY OPSTAR$10,263
- COROFLOW UPGRADE KIT$2,307
- ABSOLUTE PRO$1,650
How this compares
$200,457 in reported general payments places this provider in the 95th percentile of 1,528 internal medicine providers in Louisiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 373 | $88,374 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 45 | $41,412 |
| Buprenorphine Hcl | 41 | $4,066 |
| Clonazepam | 135 | $849 |
| Gabapentin | 75 | $732 |
| Ventolin HfaAlbuterol Sulfate | 12 | $634 |
| Butalbital-Acetaminophen-CaffeButalb/Acetaminophen/Caffeine | 18 | $563 |
| Ibuprofen | 44 | $393 |
| Quetiapine Fumarate | 27 | $165 |
| Zolpidem Tartrate | 13 | $43 |
| Lorazepam | 16 | $30 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Indivior Inc.Suboxone | $150 | $41,41245 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,528 internal medicine providers in Louisiana.
Other internal medicine in Covington
- David TranCovington$32K
- Rachael MurphyCovington$14K
- Donna RyanBaton Rouge$991K
- Steven DeitelzweigNew Orleans$939K
- Amanda FontenotMarrero$142K
- John SchwabBaton Rouge$122K
- Daniel EnglertNew Orleans$74K
- Everett BrownGretna$71K
- Rajan KhannaShreveport$54K
- Samuel StaggEunice$54K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.